40多家公司改道再战IPO 投行人士：业绩波动较大或规范性不足企业会在审核问询阶段“撤单”

Core Viewpoint - The IPO market has seen a resurgence this year, with over 40 companies reapplying for A-share listings after previously withdrawing their applications, indicating a strategic shift in their approach to capital markets [1][2]. Group 1: Companies' Strategic Shifts - Many companies that previously aimed for the Shanghai and Shenzhen boards are now targeting the Beijing Stock Exchange (北交所) for their IPOs, reflecting a change in strategy [2][3]. - For instance, 中科仪, which withdrew its application for the Sci-Tech Innovation Board (科创板) in May 2021, has now reappeared at the 北交所 after a four-year hiatus [2]. - 百英生物 shifted from the创业板 to the 北交所, adjusting its fundraising target from 10.5 billion yuan to 4.91 billion yuan [3]. Group 2: Adjustments in Fundraising - Companies are generally lowering their fundraising targets and adjusting their project allocations in response to previous scrutiny and market conditions [4][5]. - 尚水智能 reduced its fundraising target from 10.02 billion yuan to 5.87 billion yuan when shifting from the Sci-Tech Innovation Board to the创业板 [5]. - 惠科股份 also decreased its fundraising amount from 95 billion yuan to 85 billion yuan while improving its operational performance, with revenues projected to grow from 271.34 billion yuan in 2022 to 403.10 billion yuan in 2024 [6]. Group 3: Market Environment and Company Performance - The current market environment has prompted companies to reassess their positions and align their offerings with the characteristics of different boards, with the 北交所 being more accommodating to growth-oriented small and medium enterprises [3][4]. - Companies like 惠科股份 have shown significant recovery in their financial performance, with net profits expected to rise from -20.97 billion yuan in 2022 to 36.73 billion yuan in 2024, driven by improved market conditions and strategic adjustments [6].